INmune Bio Climbs on Plan to Report Alzheimer's Study Data Monday

Dow Jones

Jun 27

By Josh Beckerman

INmune Bio shares jumped after the company said it would report top-line data from an Alzheimer's disease drug trial on Monday.

The stock rose 78%, to $11.20, after hours Thursday. It closed the regular session at $6.28, down about 15%, but has gained about 34% so far this year.

The Boca Raton, Fla., company said it would present data for its XPro drug candidate from the Phase 2 MINDFuL trial in a conference call set for 8:00 a.m. ET on Monday. The trial includes patients with mild cognitive impairment or Alzheimer's disease with brain inflammation.

INmune previously said the primary endpoint is a change from baseline in cognitive scores measured with the Early and Mild Alzheimer's Cognitive Composite.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

June 26, 2025 18:48 ET (22:48 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2546752465"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2546752465\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2546752465?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-27 06:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2546752465","market":"sg","top_or_hot":-1,"title":"INmune Bio Climbs on Plan to Report Alzheimer's Study Data Monday","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  INmune Bio shares jumped after the company said it would report top-line data from an Alzheimer's disease drug trial on Monday. \n</p>\n<p>\n  The stock rose 78%, to $11.20, after hours Thursday. It closed the regular session at $6.28, down about 15%, but has gained about 34% so far this year. \n</p>\n<p>\n  The Boca Raton, Fla., company said it would present data for its XPro drug candidate from the Phase 2 MINDFuL trial in a conference call set for 8:00 a.m. ET on Monday. The trial includes patients with mild cognitive impairment or Alzheimer's disease with brain inflammation. \n</p>\n<p>\n  INmune previously said the primary endpoint is a change from baseline in cognitive scores measured with the Early and Mild Alzheimer's Cognitive Composite. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 26, 2025 18:48 ET (22:48 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>INmune Bio Climbs on Plan to Report Alzheimer's Study Data Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nINmune Bio Climbs on Plan to Report Alzheimer's Study Data Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-06-27 06:48</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  INmune Bio shares jumped after the company said it would report top-line data from an Alzheimer's disease drug trial on Monday. \n</p>\n<p>\n  The stock rose 78%, to $11.20, after hours Thursday. It closed the regular session at $6.28, down about 15%, but has gained about 34% so far this year. \n</p>\n<p>\n  The Boca Raton, Fla., company said it would present data for its XPro drug candidate from the Phase 2 MINDFuL trial in a conference call set for 8:00 a.m. ET on Monday. The trial includes patients with mild cognitive impairment or Alzheimer's disease with brain inflammation. \n</p>\n<p>\n  INmune previously said the primary endpoint is a change from baseline in cognitive scores measured with the Early and Mild Alzheimer's Cognitive Composite. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 26, 2025 18:48 ET (22:48 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INMB","symbol_name":"INmune Bio Inc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2546752465","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2546752465","pubTimestamp":1750978080,"columns":[{"name":"Data Report","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"INmune Bio shares jumped after the company said it would report top-line data from an Alzheimer's disease drug trial on Monday.The stock rose 78%, to $11.20, after hours Thursday. It closed the regular session at $6.28, down about 15%, but has gained about 34% so far this year.The Boca Raton, Fla., company said it would present data for its XPro drug candidate from the Phase 2 MINDFuL trial in a conference call set for 8:00 a.m. ET on Monday. The trial includes patients with mild cognitive impairment or Alzheimer's disease with brain inflammation.INmune previously said the primary endpoint is a change from baseline in cognitive scores measured with the Early and Mild Alzheimer's Cognitive Composite.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INMB":"INmune Bio Inc","BK4139":"生物科技"},"translate_title":"INmune Bio计划周一报告阿尔茨海默病研究数据，股价攀升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INMB":0.9},"content_text":"By Josh Beckerman \n\n\n \n\n\n  INmune Bio shares jumped after the company said it would report top-line data from an Alzheimer's disease drug trial on Monday. \n\n\n  The stock rose 78%, to $11.20, after hours Thursday. It closed the regular session at $6.28, down about 15%, but has gained about 34% so far this year. \n\n\n  The Boca Raton, Fla., company said it would present data for its XPro drug candidate from the Phase 2 MINDFuL trial in a conference call set for 8:00 a.m. ET on Monday. The trial includes patients with mild cognitive impairment or Alzheimer's disease with brain inflammation. \n\n\n  INmune previously said the primary endpoint is a change from baseline in cognitive scores measured with the Early and Mild Alzheimer's Cognitive Composite. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 26, 2025 18:48 ET (22:48 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}